ORLANDO, Fla., March 20 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the “Company” or “Telzuit”) announced today that it has secured its first round of pre-orders for its Bio-Patch Wireless Holter Monitor System. The Company has secured 500 pre-orders of the Bio-Patch with physicians in the local Orlando area. Telzuit expects the pre-orders to be filled and operating by May 1, 2006.
Warren D. Stowell, newly appointed CEO of Telzuit, commented, “This announcement marks the soft launch of our Bio-Patch System and the initial market penetration of the product. The Telzuit team has done a tremendous job streamlining the final phases of the Bio-Patch’s development, and we are thrilled to be taking orders in the marketplace.”
Mr. Stowell added, “While we have not yet commenced the Bio-Patch’s broad market roll-out, feedback from our initial marketing efforts has been exceptional, and we believe today’s announced soft launch alone will result in solid revenue. Assuming a 40% usage rate, we believe these 500 pre-orders could result in approximately $2 million in sales in 2006. I commend our employees for their hard work, and look forward to updating our progress as the year continues.”
Separately, Telzuit announced today that the Securities and Exchange Commission has declared effective the Company’s Registration Statement on Form SB-2, registering effective the corresponding shares of Telzuit common stock.
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The company is in the final stages of launching its first product, the FDA-approved Bio-Patch Wireless Heart Monitor. The Bio-Patch is a full 12-lead, completely wireless Holter monitor, which is new to the marketplace. In conjunction with its strategic partners, Telzuit is also building its own dedicated intranet platform to handle several of the products it will be releasing, including the Bio-Patch. Telzuit is based in Orlando, Florida. For more information Telzuit, its business model, and its products, please visit the company’s website: http://www.telzuit.com .
Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contact: Telzuit Medical Technologies, Inc. James Tolan, Senior Vice President 407-354-1222 Brainerd Communicators, Inc. Jennifer Gery (media) Todd St.Onge (investors) 212-986-6667
Telzuit Medical Technologies, Inc.
CONTACT: James Tolan, Senior Vice President of Telzuit MedicalTechnologies, Inc., +1-407-354-1222; or Jennifer Gery (media) or ToddSt.Onge (investors), both of Brainerd Communicators, Inc. for TelzuitMedical Technologies, Inc., +1-212-986-6667
Web site: http://www.telzuit.com/